PDF herunterladen
Arzneimittelforschung 2009; 59(4): 195-201
DOI: 10.1055/s-0031-1296385
Analgesics · Anti-inflammatories · Antiphlogistics · Antirheumatic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Design and Synthesis of Some (S)-2-(6-Methoxynaphthalen-2-yl)-N-substituted Ethyl Propanamide Derivatives as Potent Non-ulcerogenic Anti-inflammatory and Analgesic Agents

Barkin Berk
1   Yeditepe University, Faculty of Pharmacy, Istanbul, (Turkey)
,
Dilek Demir Erol
1   Yeditepe University, Faculty of Pharmacy, Istanbul, (Turkey)
,
Esra Kupeli
1   Gazi University, Faculty of Pharmacy, Ankara, (Turkey)
,
Erdem Yesilada
1   Yeditepe University, Faculty of Pharmacy, Istanbul, (Turkey)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Dezember 2011 (online)

    Lizenzen und Reprints

Abstract

The carboxylic acid group of the antiinflammatory drug, (S)-2-(6-methoxy-naphthalen-2-yl) propanoic acid, naproxen (CAS 22204-53-1) was reacted with the substituted ethylamine derivatives to form (S)-2-(6-methoxynaphthalen-2-yl)-N-substituted ethyl propanamides by using N,N’-dicyclohexyl carbodiimide (DCC) and 4-(dimethylamino) pyridine (DMAP). Anti-inflammatory and analgesic activities of the compounds were assessed in vivo by carrageenan-induced hind paw edema and p-benzoquinone induced abdominal contraction tests in mice, respectively. In addition, the ulcerogenic properties of the new compounds were evaluated, and compared to that of naproxen. Among the newly synthesized compounds, compound 2f showed the highest analgesic and antiinflammatory activity at 100 mg/kg oral dose, without inducing any gastric lesion. Although this compound induced less gastric lesions than naproxen, it was found to have less anti-inflammatory and analgesic activity when compared to indometacin (CAS 53-86-1). These new compounds therefore deserve further attention to develop new lead drugs.

Key words

Analgesics - Antiinflammatories - CAS 53-86-1 - CAS 22204-53-1 - Ethyl propanamide derivatives - Naproxen - Ulcerogenesis
 

  • References

  • 1 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; Jun 23 231 (25) 232-235
    CrossrefPubMedGoogle Scholar
  • 2 Busson M. Update on ibuprofen: review article. J Int Med Res. 1986; 14: 53-62
    PubMedGoogle Scholar
  • 3 Cryer B. NSAID-associated deaths: The rise and fall of NSAID-associated GI mortality. Am J Gastroenterol. 2005; 100: 1694-1695
    CrossrefPubMedGoogle Scholar
  • 4 Go MF. Drug injury in the upper gastrointestinal tract: Nonsteroidal anti-inflammatory drugs. Gastrointest Endosc Clin N Am. 2006; 16: 83-97
    CrossrefPubMedGoogle Scholar
  • 5 James MW, Hawkey CJ. Assessment of non-steroidal antiinflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol. 2003; 56: 146-155
    CrossrefPubMedGoogle Scholar
  • 6 Lazzaroni M, Bianchi PG. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004; 20 (2) 48-58
    PubMedGoogle Scholar
  • 7 Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: A review of current treatment options. DrugSaf. 2006; 29: 119-132
    PubMedGoogle Scholar
  • 8 Mounier G, Guy C, Berthoux F, Beyens MN, Ratrema M, Ollagnier M. Severe renal adverse events with arylcar-boxylic non-steroidal anti-inflammatory drugs: Results of an eight-year French national survey. Therapie. 2006; 61: 255-266
    CrossrefPubMedGoogle Scholar
  • 9 Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. 2006; 164: 881-889
    CrossrefPubMedGoogle Scholar
  • 10 Zadrazil J. Nonsteroidal antiinflammatory drugs and the kidney. Vnitr Lek. 2006; 52: 686-690
    PubMedGoogle Scholar
  • 11 Adebayo D, Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy. Postgrad Med J. 2006; 82: 186-191
    CrossrefPubMedGoogle Scholar
  • 12 Dogne JM, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem. 2005; 48: 2251-2257
    CrossrefPubMedGoogle Scholar
  • 13 Scheen AJ. Withdrawal of rofecoxib (Vioxx): What about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs. Rev Med Liege. 2004; 59: 565-569
    PubMedGoogle Scholar
  • 14 Chiroli V, Benedini F, Ongini E, Del Soldato P. Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitro derivatives of aspirin. Eur J Med Chem. 2003; 38: 441-446
    CrossrefPubMedGoogle Scholar
  • 15 Nitronaproxen: AZD 3582 HCT 3012 naproxen nitroxybu-tylester NO-naproxen. Drugs R D. 2006; 7: 262-266
    CrossrefPubMedGoogle Scholar
  • 16 Holm L, Phillipson M, Perry MA. NO-flurbiprofen maintains duodenal blood flow, enhances mucus secretion contributing to lower mucosal injury. Am J Physiol Gastrointest Liver Physiol. 2002; 283: G1090-G1097
    PubMedGoogle Scholar
  • 17 Wallace JL, Muscará MN, De Nucci G, Zamuner S, Cirino G, Del Soldato P et al Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-a-methyl-[l.l’-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]. J Pharmacol Exp Ther. 2004; 309: 626-633
    CrossrefPubMedGoogle Scholar
  • 18 Wallace JL, Reuter B, Cicala C, McKnight W, Grisham M, Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol. 1994; 257: 249-255
    CrossrefPubMedGoogle Scholar
  • 19 Rigas B, Kashfi K. Nitric oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med. 2004; 10: 324-330
    CrossrefPubMedGoogle Scholar
  • 20 Wallace JL, McKnight W, Reuter B, Cicala C, Grisham M, Cirino G. Nitric-oxide releasing NSAID derivatives - antiinflammatory without gastropathy. Gastroenterology. 1994; 106: A208
    PubMedGoogle Scholar
  • 21 Wallace JL, Reuter BK, Cirino G. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: A novel approach for reducing gastrointestinal toxicity. J Gastroenterol Hepatol. 1994; 9 (1) S40-S44
    CrossrefPubMedGoogle Scholar
  • 22 Csont T, Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: Beyond vascular nitrate tolerance. Pharmacol Ther. 2005; 105: 57-68
    CrossrefPubMedGoogle Scholar
  • 23 Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther. 1994; 8: 489-499
    CrossrefPubMedGoogle Scholar
  • 24 Hu R, Siu CW, Lau EO, Wang WQ, Lau CP, Tse HF. Impaired nitrate-mediated dilatation could reflect nitrate tolerance in patients with coronary artery disease. Int J Cardiol. 2007; 120: 351-356
    CrossrefPubMedGoogle Scholar
  • 25 Rainsford KD. Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl. 1989; 163: 9-16
    PubMedGoogle Scholar
  • 26 Lanza FL, Nelson RS, Chen TT et al The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers: a gastroscopic and photographic study. Dig Dis Sci. 1979; 24: 823-828
    CrossrefPubMedGoogle Scholar
  • 27 Cioli V, Putzolu S, Rossi V, Scorza BP, Corradino C. The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol Appl Pharmacol. 1979; Sep 15 50 (2) 283-289
    CrossrefPubMedGoogle Scholar
  • 28 Akgün H, Tozkoparan B, Ertan M, Aksu F, Inan SY. Synthesis of some 2-arylpropionic acid amides as prodrugs. Arzneimittelforschung. 1996; 46 (9) 891-894
    PubMedGoogle Scholar
  • 29 Shanbhag VR, Crider AM, Gokhale R, Harpalani A, Dick RM. Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J Pharm Sci. 1992; 81 (2) 149-154
    CrossrefPubMedGoogle Scholar
  • 30 Khanand MSY, Akhter M. Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur J Med Chem. 2005; 40: 371-376
    CrossrefPubMedGoogle Scholar
  • 31 Cocco MT, Congiu C, Onnis V, Morelli M, Cauli O. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem. 2003; 38 (5) 513-518
    CrossrefPubMedGoogle Scholar
  • 32 Mahfouz NM, Omar FA, Aboul-Fadl T. Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccini-mide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur J Med Chem. 1999; 34: 551-562
    PubMedGoogle Scholar
  • 33 Möller NL, Dietzel KE, Schneider HT, Brune K. Novel 5-aminosalicylic acid NSAID conjugates: synthesis; pharmacological and toxicological properties. Eur J Med Chem. 1989; 2: 463-469
    PubMedGoogle Scholar
  • 34 Ranatunge RR, Augustyniak ME, Dhawan V, Ellis JL, Garvey DS, Janero DR, et al. Synthesis and anti-inflammatory activity of a series of N-substituted naproxen glycolamides: nitric oxide-donor naproxen prodrugs. Bioorg Med Chem. 2006; 14: 2589-2599
    CrossrefPubMedGoogle Scholar
  • 35 Berk B, Aktay G, Yesilada E, Ertan M. Synthesis and pharmacological activities of some new 2-[1-(6-methoxy-2-naphthyl)ethyl]-6-(substituted)benzylidene thiazolo[3,2-b]-1,2,4-triazole-5(6H)-one derivatives. Pharmazie. 2001; 56 (8) 613-616
    PubMedGoogle Scholar
  • 36 Bergeron RJ, Huang G, McManis JS, Yao H, Nguyen JN. Synthesis and biological evaluation of aminopolyamines. J Med Chem. 2005; May 5 48 (9) 3099-3102
    CrossrefPubMedGoogle Scholar
  • 37 Kasahara Y, Hikino H, Tsurufuji S, Watanabe M, Ohuchi K. Anti-inflammatory actions of ephedrines in acute inflammations. Planta Med. 1985; 51: 325-331
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 38 Okun R, Liddon SC, Lasagna L. The effect of aggregation, electric shock and adrenergic blocking drugs on inhibition of the “writhing syndrome”. J Pharmacol Exp Ther. 1963; 139: 107-109
    PubMedGoogle Scholar
  • 39 Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indometacin, as selective cyclooxygenase-2 Inhibitors. J Med Chem. 2000; 43: 2860-2870
    CrossrefPubMedGoogle Scholar